In this episode, the panel considers safety questions surrounding OX40-targeted therapy in light of the Kaposi sarcoma (KS) ...
The burden of atopic dermatitis (AD) -- for patients, their families, and society -- is vast and increasing. AD affects approximately 10% to 30% of children and 2% to 10% of adults in developed ...
Please provide your email address to receive an email when new articles are posted on . Kyowa Kirin reported positive phase 2 study results for KHK4083 in treating atopic dermatitis compared with ...
SAN DIEGO, SHANGHAI and SYDNEY, Aug. 15, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), a clinical stage biotechnology company developing innovative and differentiated therapies for ...
Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody Amlitelimab shows ...
ORLANDO, Fla. — In a phase 3 atopic dermatitis (AD) trial, rocatinlimab, a novel therapy that targets T cells expressing the OX40 receptor, showed efficacy on both coprimary and key secondary ...
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced the U ...
PARAMUS, N.J., April 16, 2018 /PRNewswire/ -- Glenmark Pharmaceuticals, a global pharmaceutical company, today announced the initiation of a Phase 2b clinical trial of GBR 830, a novel, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results